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Abstract
Background: The association of platelet reactivity and clinical outcomes, especially stent thrombosis, was not so
clear. We sought to investigate whether high platelet reactivity affects clinical outcomes of patients with drug
eluting stents (DESs) implantation.
Methods: All enrolled individuals treated with DESs implantation were evaluated by PL-11, using sequentially
platelet counting method. The primary end point was the occurrence of definite and probable stent thrombosis at
2 years. The secondary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including
all cause death, spontaneous myocardial infarction (MI), target vessel revascularization (TVR), and ischemic stroke.
Results: A total of 1331consecutive patients were enrolled at our center. There were 91 patients (6.8 %) identified
with high platelet reactivity (HPR) on aspirin, and 437 patients (32.9 %) with HPR on clopidogrel. At 2-year follow-
up, the incidence of stent thrombosis was significantly higher in patients with HPR on aspirin (9.9 % vs. 0.4 %, p < 0.
001), and HPR on clopidogrel (3.0 % vs. 0.1 %, p < 0.001). There were increased MACCE in the HPR on aspirin group
(16.5 % vs. 8.5 %, p = 0.021), mainly driven by the higher all cause death (7.7 % vs. 1.6 %, p = 0.002) and MI (9.9 % vs.
1.9 %, p < 0.001) in the HPR on aspirin group. Similarly, the rate of MACCE was higher in the HPR on clopidogrel
group (12.4 % vs. 7.4 %, p = 0.004). No differences in all bleeding and hemorrhagic stroke were observed.
Conclusions: The present study demonstrated that high platelet reactivity on both aspirin and clopidogrel were
associated with incremental stent thrombosis following DESs implantation.
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Background
Stent thrombosis was recognized as an important compli-
cation of percutaneous coronary intervention (PCI), ran-
ging around 0.5 to 2 % with the use of drug-eluting stents
(DES) [1, 2], but stent thrombosis had a high risk of myo-
cardial infarction and cardiac death [3, 4]. Effective dual
anti-platelet therapy (DAPT) with aspirin and clopidogrel is
mandatory after DES implantation, due to DES inducing
platelet adhesion, activation and thrombus formation. Anti-
platelet insufficiency, especially high platelet reactivity on
aspirin and clopidogrel, has been considered to play an im-
portant role in stent thrombosis [5].
There are several studies exploring the association be-
tween platelet reactivity and stent thrombosis [5–8],
however, some limitations still existed, such as low-risk
population, low event rates, and conflicted results.
Moreover, the VerifyNow P2Y12 assay was widely used
in these studies, which has been reported to be nonflex-
ible, very expensive, limited hematocrit and platelet
count, and just moderate agreement with other platelet
function tests [9, 10]. However, sequentially platelet
counting method by PL-11 (SINNOWA Co., Nanjing,
China) was a novel analyzer for platelet reactivity test by
automatic impedance technique [11]. Therefore, this
prospective study was designed to assess the association
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between platelet reactivity with the novel automatic
platelet aggregometer and stent thrombosis among pa-
tients with DES implantation.
Methods
Study population
From July 2012 to May 2014, a total of 3600 consecutive
real-world patients who treated with DES implantation
from our center were considered candidates for this
registry. Finally 1331 patients were included in this study
according to the inclusion and exclusion criteria. Inclu-
sion criteria were as follows: age >18 years, and success-
ful PCI in at least one major epicardial coronary artery.
Exclusion criteria were demonstrated in Fig. 1. Add-
itional exclusion criteria included pregnancy, a platelet
count < 10*109 /L and suspected intolerance to one of
the study drugs.
Interventional procedure and medications
All interventional procedures were performed in accord-
ance with the current guidelines. The type of DES selec-
tion, procedural technique, use of glycoprotein IIb/IIIa
inhibitors, intravascular ultrasound, fractional flow re-
serve, and optical coherence tomography were at the
discretion of the operators. A loading dose of aspirin
and clopidogrel of at least 300 mg were administered
prior to the index procedure. Heparin was used during
the procedure to maintain an activated clotting time
more than 250 s. Total creatine kinase (CK), CK-MB,
and troponin were dynamically measured until 72 h
post-procedure. After the intervention, all patients
received 100 mg/day aspirin for life and clopidogrel
(75 mg/day) for at least 12 months.
Platelet function test
Platelet reactivity was assessed in all patients before hep-
arin administered during procedure in the Lab room.
PL-11 analyzer (SINNOWA Co., Nanjing, China) was
used for the test [11, 12]. With standardized and easier
test method, the analyzer gives more exact and stable re-
sults of platelet maximum aggregation ratio (MAR%).
PL-11 analyzer measures the platelet function by “se-
quentially platelet counting method”, and the analyzer
automatically and sequentially counts (impedance tech-
nology) the numbers of platelet in the citrated whole
blood sample before and after adding agonists in fixed
time interval during the whole testing progress. For each
agonist test, 500 ul citrated whole blood sample was
transferred into a test tube, then it was placed into the
test position in the analyzer, press the “test button” the
analyzer begins to count the platelet of the sample auto-
matically two times and calculates the original platelet
number (mean value) by the first two counts, then 40 ul
of agonist was added into the sample and mixed to acti-
vate platelets aggregating. The numbers of platelet in the
sample will be decreased because aggregation. More
platelet aggregated, lower numbers of platelet existing in
the sample. After adding agonist, the analyzer continues
to measure platelet numbers in the sample for 3 times,
also in fixed time interval and get three results of plate-
let number, the lowest platelet number of the three is
used to calculate the MAR% in the following formula:
(1-lowest platelet number/initial platelet number) ×
100 %. The whole test progress is 12 min, the sample
position keeps at 37 °C and keeps swaying during the
progress, so the sample is kept in well mixed and good
condition during testing. Arachidonic acid (AA, 2 mg/
ml) and adenosine diphosphate (ADP, 50umol/L) were
used as agonists. Additionally, high platelet reactivity
(HPR) on aspirin was defined as MAR% ≥ 30 %; mean-
while, HPR on clopidogrel was defined as MAR% ≥ 55 %.
All investigators were strongly encouraged not to change
antiplatelet strategy according to the results of platelet
function test.
Study endpoints and definitions
The primary end point was the occurrence of definite
and probable stent thrombosis at 2 years, defined ac-
cording to the Academic Research Consortium (ARC)
classification [13]. The secondary endpoint was the inci-
dence of major adverse cardiovascular and cerebrovascu-
lar events (MACCE), including all cause death,
spontaneous myocardial infarction (MI), target vessel re-
vascularization (TVR), and ischemic stroke. The safety
endpoint was the risk of all bleeding and hemorrhagic
Fig. 1 Flowchart of study design. The value of ADP-MAR% was
missed in three patients. AA: arachidonic acid; MAR: maximal
aggregation ratio; ADP: adenosine diphosphate
Zhang et al. BMC Cardiovascular Disorders  (2016) 16:240 Page 2 of 9
stroke, defined according to the Bleeding Academic Re-
search Consortium (BARC) classification [14]. All deaths
were considered cardiac in origin unless a non-cardiac
cause was confirmed clinically or at autopsy. Spontan-
eous MI was diagnosed in accordance with Third Uni-
versal Definition of Myocardial Infarction [15]. Target
lesion revascularization and TVR were defined as repeat
revascularization (including PCI and coronary artery by-
pass grafting) for target lesions and target vessels, re-
spectively, in the presence of symptoms or objective
signs of ischemia. Stroke was defined as global or focal
cerebral, spinal cord, or retinal injury resulting in acute
neurological dysfunction and was further classified into
ischemic and hemorrhagic.
Follow-up
Clinical follow-up was performed either by telephone
or through a clinical office visit at 1, 6, 12, and
24 months. Repeat coronary angiography was scheduled
at 13 months after the indexed procedure unless clin-
ical reasons indicated earlier. All clinical events were
assessed by an independent committee that was blinded
to the study.
Statistical analysis
The distribution of continuous variables was assessed by
the Kolmogrov-Smirnov test. Categorical variables were
expressed as frequencies or percentages and compared
by Chi-square statistics or Fisher’s exact test. Continuous
variables were summarized as means ± standard devi-
ation (SD) or median and compared using Students’ t-
test (for normal data) and Mann–Whitney U-test (for
non-normally distributed variables). Survival curves with
time-to-event data were generated by the Kaplan-Meier
method and compared using the log-rank test. Hazard
ratios (HR) are presented along their 95 % confidence
interval (CI). Multivariable Cox proportional hazard
model including platelet reactivity, other clinical and
procedural variables was applied to identify the inde-
pendent predictors that correlated with definite and
probable stent thrombosis. Receiver-operating character-
istic (ROC) curves were generated to assess the associ-
ation between platelet reactivity and clinical outcomes.
A p value <0.05 was considered statistically significance.
All analyses were performed with the use of the statis-




A total of 1331 patients with DES implantation were fi-
nally enrolled, and baseline clinical characteristics were
showed in Table 1. The median AA-MAR% of 1331 en-
rolled patients was 18.2 %, and the median ADP-MAR%
of 1328 patients was 36.4 %. There were 91 patients
(6.8 %) identified with HPR on aspirin, and 437 patients
(32.9 %) with HPR on clopidogrel. 86.2 % of the individ-
uals were admitted with acute coronary syndromes
(ACS). Baseline clinical characteristics between HPR on
aspirin group and normal platelet reactivity (NPR) on as-
pirin group were comparable. Patients in the NPR on
clopidogrel group were more likely males (77.7 %) and
ACS (87.8 %), when compared to the HPR on clopido-
grel group (70.9 %, p = 0.008; 82.8 %, p = 0.018).
Lesions and procedural characteristics
No differences in the lesions and procedural characteris-
tics were observed between HPR on aspirin and NPR on
aspirin group (Table 2). In addition, there were also no
differences between HPR on clopidogrel and NPR on
clopidogrel group, except for more frequent use of
glycoprotein IIb/IIIa Inhibitors for patient with NPR on
clopidogrel (12.0 % vs. 8.2 %, p = 0.048).
High platelet reactivity and clinical outcomes
After a median follow-up of 2 years, there were 9 (9.9 %)
definite and probable stent thrombosis events in the HPR
on aspirin group and 5 (0.4 %) in the NPR on aspirin
group (p < 0.001, Table 3, Fig. 2a), with the detailed infor-
mation of these 14 patients listed in Table 4. The risk of
stent thrombosis in the HPR on clopidogrel group was
3.0 %, much higher than 0.1 % in the NPR on clopidogrel
group (Fig. 2b). By Cox regression multivariable analysis,
the independent predictors of definite and probable stent
thrombosis were AA-MAR% (HR: 1.844, 95 % CI: 1.348 to
2.522, p < 0.001), ADP-MAR% (HR: 1.680, 95 % CI: 1.128
to 2.502, p = 0.011), and total implanted stents (HR: 1.421,
95 % CI: 1.108 to 1.822, p = 0.006).
The area under ROC (AUC) of AA-MAR% predicting
stent thrombosis was 0.808 (95 % CI: 0.695, 0.922; p <
0.001), with the cutoff value of 34.5 % (sensitivity:
64.3 %, specificity: 92.1 %, Additional file 1: Figure S1),
which was comparable with the AUC of ADP-MAR%
(0.747, 95 %: 0.623, 0.870, p = 0.001; p = 0.087 for AUC
comparison), with the cutoff value of 56.4 % (sensitivity:
57.1 %, specificity: 90.7 %).
There were 15 (16.5 %) composite MACCEs in the
HPR on aspirin group and 106 (8.5 %) in the NPR
on aspirin group (p = 0.021, Fig. 3a), mainly driven
by the higher rates of all cause death (7.7 %) and
MI (9.9 %) in the HPR on aspirin group compared
with those in the NPR on aspirin group (1.6 %, p =
0.002; 1.9 %, p < 0.001). Similarly, the rate of
MACCE was 12.4 % in the HPR on clopidogrel
group, higher than 7.4 % in the NPR on clopidogrel
group (p = 0.004, Fig. 3b), mainly due to higher rates
of all cause death (5.3 %) and MI (4.8 %) in the
HPR on clopidogrel group.
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No differences in all bleeding and hemorrhagic stroke
were observed between NPR on aspirin group and HPR on
aspirin group, without significant difference found between
NPR on clopidogrel group and HPR on clopidogrel group.
Discussion
The major findings of this prospective study were that:
1) There were 6.8 % identified with high platelet
reactivity on aspirin, and 32.9 % with high platelet re-
activity on clopidogrel among patient undergoing PCI;
2) high platelet reactivity on both aspirin and clopido-
grel were independent predictors of 2-year stent
thrombosis following DESs implantation; and 3) there
were no significant association between high platelet
reactivity on aspirin/clopidogrel and any bleeding/
hemorrhagic stroke.










Age, yrs 64.19 ± 10.06 65.63 ± 9.75 0.189 63.96 ± 10.23 64.98 ± 9.60 0.082
Male, n (%) 936 (75.5) 67 (73.6) 0.706 692 (77.7) 310 (70.9) 0.008
BMI, kg/mm2 24.70 ± 3.01 24.55 ± 3.01 0.649 24.65 ± 2.95 24.78 ± 3.12 0.449
Hypertension, n (%) 888 (71.6) 66 (72.5) 0.905 644 (72.3) 307 (70.3) 0.438
Hyperlipidemia, n (%) 318 (27.4) 23 (25.6) 0.806 236 (28.3) 105 (25.4) 0.281
Diabetes, n (%) 328 (26.5) 24 (26.4) NS 239 (26.8) 112 (25.6) 0.691
Current smoking, n (%) 482 (39.2) 33 (36.7) 0.656 356 (40.3) 159 (36.7) 0.229
ACS, n (%) 1072 (86.5) 75 (82.4) 0.272 782 (87.8) 362 (82.8) 0.018
eGFR < 60 ml/min/1.73 m2, n (%) 122 (10.1) 8 (9.2) NS 94 (10.9) 36 (8.4) 0.170
Prior stroke, n (%) 138 (11.2) 11 (12.2) 0.731 93 (10.5) 56 (12.9) 0.196
Prior PCI, n (%) 236 (19.2) 15 (16.7) 0.676 161 (18.2) 89 (20.6) 0.331
LVEF, % 59.80 ± 9.33 58.50 ± 9.89 0.275 59.59 ± 9.27 59.94 ± 9.61 0.587
hsCRP, ug/ml 31.94 ± 8.88 32.84 ± 9.16 0.400 31.98 ± 8.80 32.13 ± 9.11 0.804
Agents in hospital
Aspirin, 100 mg/d 1216 (98.1) 90 (98.9) NS 881 (98.9) 428 (97.9) 0.218
Clopidogrel, 75 mg/d 1203 (97.0) 88 (96.7) 0.751 863 (96.9) 426 (97.5) 0.606
Agents at 2 years
Aspirin (100 mg/d), n (%) 1142 (92.1) 81 (89.0) 0.317 800 (89.8) 398 (91.1) 0.493
Clopidogrel (75 mg/d), n (%) 806 (65.0) 57 (62.6) 0.650 570 (64.0) 266 (61.9) 0.277
BMI body mass index, ACS acute coronary syndrome, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, LVEF left ventricular ejection
fraction, hsCRP high sensitivity C reactive protein, NPR normal platelet reactivity, HPR high platelet reactivity










Multi-vessel disease, n (%) 517 (59.2) 41 (63.1) 0.601 363 (59.6) 194 (59.1) 0.889
Bifurcation lesion, n (%) 407 (32.8) 35 (38.5) 0.300 301 (33.8) 141 (32.3) 0.578
Thrombus-containing lesions, n (%) 113 (9.3) 5 (5.7) 0.336 77 (8.9) 41 (9.5) 0.683
IIb/IIIa Inhibitor, n (%) 122 (10.8) 7 (8.6) 0.709 96 (12.0) 33 (8.2) 0.048
DES used, n (%) 1240 (100) 91 (100) NS 891 (100) 437 (100) NS
Total implanted stent 2.78 ± 1.72 2.58 ± 1.61 0.287 2.81 ± 1.76 2.69 ± 1.62 0.235
Mean stent diameter, mm 3.08 ± 0.38 3.03 ± 0.34 0.313 3.08 ± 0.38 3.05 ± 0.39 0.155
Total stent length, mm 72.14 ± 48.69 65.06 ± 42.73 0.187 72.61 ± 49.14 69.77 ± 46.65 0.332
Complete revascularization, n (%) 823 (67.9) 59 (67.0) 0.906 598 (68.8) 281 (65.7) 0.256
Final TIMI grade 3, n (%) 1199 (98.2) 88 (98.9) NS 860 (98.3) 424 (98.1) 0.827
Heparin volume, units 7915.11 ± 2027.05 8085.00 ± 1945.01 0.503 7892.79 ± 2029.11 7999.97 ± 2012.82 0.421
DES drug-eluting stent, TIMI thrombolysis in myocardial infarction, NPR normal platelet reactivity, HPR high platelet reactivity
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Antiplatelet therapy is the cornerstone of preventing
stent thrombosis in patients after DESs implantation,
but at the cost of higher bleeding risk, which has been
the Achilles’ heel for these patients. Platelet function test
focusing on the individual’s response to antiplatelet ther-
apy, was expected to select the most optimal agents and
dosage for these patients, in order to reduce the risk of
stent thrombosis and bleeding. Indeed, the ADAPT-
DES (Platelet reactivity and clinical outcomes after cor-
onary artery implantation of drug-eluting stents) study,
prospectively enrolling 8665 patients after PCI, showed
that high platelet reactivity on clopidogrel was an inde-
pendent predictor of stent thrombosis, but was also
protective against clinically relevant bleeding. However,
several other studies with different population had the
conflicted results [6, 8]. The present study with a novel
method confirmed the data from ADAPT-DES, indicat-
ing that platelet function test, combining with clinical
and procedural factors, could be at least useful for pre-
dicting stent thrombosis for PCI patients.











Definite/probable Stent thrombosis 1 0 NS 0 1 0.329
All cause death 0 0 NS 0 0 NS
Cardiac death 0 0 NS 0 0 NS
Spontaneous MI 2 0 NS 0 2 0.108
TLR 1 0 NS 0 1 0.329
TVR 1 0 NS 0 1 0.329
Ischemic stroke 8 (0.6) 0 NS 4 (0.4) 4 (0.9) 0.451
All bleeding 39 (3.1) 3 (3.3) 0.762 30 (3.4) 12 (2.7) 0.619
Hemorrhagic stroke 3 (0.2) 0 NS 3 (0.3) 0 0.555
MACCE 10 (0.8) 0 NS 4 (0.5) 6 (1.4) 0.090
At 1 years
Definite/probable Stent thrombosis 3 (0.2) 8 (8.8) < 0.001 1 (0.1) 10 (2.3) < 0.001
All cause death 8 (0.6) 2 (2.2) 0.146 3 (0.3) 7 (1.6) 0.018
Cardiac death 2 (0.2) 2 (2.2) 0.025 1 (0.1) 3 (0.7) 0.107
Spontaneous MI 17 (1.4) 3 (3.3) 0.152 10 (1.1) 10 (2.3) 0.147
TLR 30 (2.4) 0 (0) 0.260 25 (2.8) 5 (1.1) 0.075
TVR 31 (2.5) 0 (0) 0.265 25 (2.8) 6 (1.4) 0.123
Ischemic stroke 9 (0.7) 1 (1.1) 0.509 9 (1.0) 1 (0.2) 0.180
All bleeding 64 (5.2) 3 (3.3) 0.619 48 (5.4) 19 (4.3) 0.505
Hemorrhagic stroke 5 (0.4) 0 NS 3 (0.3) 2 (0.5) 0.666
MACCE 40 (3.2) 5 (5.5) 0.228 30 (3.4) 15 (3.4) 0.951
At 2 years
Definite/probable Stent thrombosis 5 (0.4) 9 (9.9) < 0.001 1 (0.1) 13 (3.0) < 0.001
All cause death 20 (1.6) 7 (7.7) 0.002 3 (0.3) 23 (5.3) < 0.001
Cardiac death 4 (0.3) 7 (7.7) < 0.001 1 (0.1) 10 (2.3) < 0.001
Spontaneous MI 23 (1.9) 9 (9.9) < 0.001 11 (1.2) 21 (4.8) < 0.001
TLR 60 (4.8) 5 (5.5) 0.799 51 (5.7) 14 (3.2) 0.057
TVR 65 (5.2) 5 (5.5) 0.809 51 (5.7) 19 (4.3) 0.360
Ischemic stroke 16 (1.3) 2 (2.2) 0.352 12 (1.3) 6 (1.4) NS
All bleeding 118 (10.0) 8 (9.2) NS 93 (10.9) 33 (7.9) 0.110
Hemorrhagic stroke 8 (0.6) 0 (0) NS 4 (0.4) 4 (0.9) 0.451
MACCE 106 (8.5) 15 (16.5) 0.021 66 (7.4) 54 (12.4) 0.004
MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, MACCE adverse cardiovascular and cerebrovascular events, NPR
normal platelet reactivity, HPR high platelet reactivity
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In contrast with our findings, ADAPT-DES study did
not identify the incremental stent thrombosis in patients
with high platelet reactivity on aspirin. This difference
might be due to the differences in population, platelet
testing methods, as well as duration of follow-up. In-
deed, there are other clinical factors to affect platelet
reactivity, such as current smoking, diabetes, and hyper-
lipidemia, which may increase the incidence of high
platelet reactivity on aspirin and the risk of adverse clin-
ical outcomes. However, multivariable Cox proportional
hazard model was used in the present study to demon-
strate that high platelet reactivity on aspirin was the in-
dependent predictor of stent thrombosis, apart from
clinical and procedural factors. Certainly, this new find-
ings need be verified in the further clinical trials.
Although the preliminary association between high
platelet reactivity and stent thrombosis was estab-
lished, several randomized clinical trials on adjust
treatment based on platelet function test in PCI pa-
tients had the negative results [16–18]. In the ARC-
TIC (The Assessment by a Double Randomization of
a Conventional Antiplatelet Strategy versus a Monitoring-
guided Strategy for Drug-Eluting Stent Implantation and
of Treatment Interruption versus Continuation 1 Year
after Stenting) study [16], 2440 PCI patients were ran-
domized to platelet function monitoring group with ther-
apy adjustment if necessary, or conventional strategy
without monitoring. After 1-year follow-up, there were no
significant improvements in clinical outcomes with plate-
let function monitoring, compared with conventional
antiplatelet therapy, which was in line with other studies
[17, 18]. The negative results might be due to the low-risk
population, low event rate, and inclusion of periprocedural
MI, which could not be prevented by platelet function
test. Of note, all these studies were performed with Verify-
Now, and other platelet assays such as PL-11 require fur-
ther investigation. In summary, the current randomized
studies do not support the routine platelet function tests
to adjust treatment for PCI patients.
Just as mentioned above, there are several methods
of platelet test assessing platelet reactivity. In the
POPULAR (Do Platelet Function Assays Predict Clin-
ical Outcomes in Clopidogrel-Pretreated Patients
Undergoing Elective PCI) study [19], the largest head-
to-head comparison among platelet test methods, only
light transmittance aggregometry (LTA), VerifyNow,
and Plateletworks had the modest association with
the primary end point (composite of all-cause death,
nonfatal acute myocardial infarction, stent thrombosis,
and ischemic stroke). However, none of these tests
could identify patients at the higher risk of bleeding
after PCI. Moreover, the study by Lemesle G [20]
showed poor agreement between LTA, VerifyNow and
vasodilatator-stimulated phosphoprotein for clopido-
grel low-response assessment. Therefore, platelet
function assays were not equally interchangeable and
the correlations among them were varied. PL-11 by
“sequentially platelet counting method” gives more
exact and stable results of platelet counting before
and after the addition of agonists in the citrated
whole blood samples, which has been demonstrated
to be correlated with LTA and VerifyNow [11]. Con-
sequently, sequentially platelet counting method by
PL-11 would bean optional device for platelet func-
tion tests.
Another two questions need to be discussed further.
First, Sheiban et al. [21] reported that PCI on unpro-
tected left main (ULM) disease had a safe long-term
Fig. 2 Definite/ probable stent thrombosis-free survival rate at 2 years. Freedom from definite/probable stent thrombosis at 2-year follow-up
a between AA-MAR%≥ 30 % (green line) and AA-MAR% < 30 % (blue line), b between ADP-MAR%≥ 55 % (green line) and ADP-MAR%< 55 %
(blue line). Abbreviations are showed in Fig. 1
Zhang et al. BMC Cardiovascular Disorders  (2016) 16:240 Page 6 of 9
(more than 10 years) outcome despite of using first-
generation DES, with low rates of recurrent events due
to index revascularization. A total of 167 patients with
ULM disease were involved in our study, in which 100
patients (59.9 %) received second-generation DES im-
plantation and 67 patients (40.1 %) with first-generation
DES. There was no significant difference in MACCE
between first- and second-generation DES, might due
to a relative small population. Second, a recent meta-
analysis [22] showed that shorter DAPT duration was
associated with higher rates of MI, lower rates of
major bleeding, and similar rates of stent thrombosis,
and cardiovascular mortality. In our study, all patients
received 100 mg/day aspirin for life and clopidogrel
(75 mg/day) for at least 12 months after the interven-
tion, without shorter DAPT duration (less than
12 months). An individualized patient approach to
DAPT duration by balancing risks of bleeding and
stent thrombosis was recommended. Therefore, the
impact of platelet reactivity test guided DAPT dur-
ation on PCI patients will be explored in our next
study.
Our data confirm the previous evidence from ADAPT-
DES and add some novel findings. First, high platelet re-
activity on aspirin was associated with stent thrombosis
after drug-eluting stent implantation apart from clopido-
grel, which was in accordance to the clinical hypothesis.
Second, the associations between platelet function tests
with 1-year thrombotic events were explored in most
previous studies, but our study showed the reduced 2-
year stent thrombosis with high platelet reactivity for the
first time. Finally, it is the first time for PL-11 used in
clinical trials, and PL-11 might bean optional device for
platelet function tests.





AA-MAR, % ADP-MAR, % CYP2C19
gene







2 15.4 60.6 NA Dual-antiplatelet for 2 years 2 0





8 35 58.4 Poor
metabolizer





3 20 58.6 NA Dual-antiplatelet for 2 years 1 0
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EH essential hypertension, DM diabetes mellitus, CKD chronic kidney disease, LAD left anterior descending, AA arachidonic acid, MAR maximal aggregation ratio,
ADP adenosine diphosphate, PCI percutaneous coronary intervention
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Study limitation
The current study has several limitations. First, none of
the 1331 patients had received therapy adjustment
according to platelet function tests, and it was not avail-
able for evaluating the effects of platelet function tests-
guided therapy adjustment on cardiovascular outcome.
Second, all enrolled patients underwent platelet function
tests before DES implantation, and it might not be pos-
sible to conduct a repeat platelet test in consideration of
the short hospitalization period in patients after PCI.
Third, there was the lack of platelet function tests post-
discharge, and we could not find time-dependent
changes in platelet activity.
Conclusions
This prospective study showedhighplatelet reactivity onboth
aspirin and clopidogrel were associated with incremental
stent thrombosis followingdrug-eluting stent implantation.
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